Scientific deep-dive
GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree
No GLP-1 is approved for PCOS anywhere. The randomized evidence is eleven trials: a low-certainty weight effect, better insulin sensitivity than metformin, and reproductive outcomes two meta-analyses grade differently.
No GLP-1 medicine is approved anywhere for polycystic ovary syndrome. Every prescription written for it is off-label, resting on a randomized evidence base that amounts to eleven trials.[1] What those trials show is a modest weight effect graded low-certainty, an insulin-sensitivity effect that looks better than metformin’s, and, depending on which analysis you read, either a meaningful improvement in periods and pregnancy rates or not enough evidence to say. Both readings are published. The newer and more careful one is the cautious one.
What PCOS treatment is aiming at
This matters before any number, because PCOS is not one problem and a drug can help with one part while doing nothing for another. The things people want changed are usually some combination of irregular or absent periods, difficulty conceiving, insulin resistance (sometimes visible as the dark neck patches of acanthosis nigricans), excess hair growth, and weight that is unusually hard to shift.
Our PCOS condition page covers the syndrome itself; this one stays on the drug evidence. Weight loss is the intervention with the longest history here, because losing a relatively small amount often restores ovulation. That is the mechanism through which a weight-loss drug could plausibly help with the reproductive side at all, rather than a direct effect on the ovary. Keep that in mind reading what follows, because it is what the trials are testing.
What the newest review found
In 2026 the European Journal of Endocrinology published a registered systematic review and meta-analysis of GLP-1 drugs in women with PCOS. It screened 9,654 studies, read 365 in full, and found 11 randomized trials worth including.[1]
| Outcome | Finding | Certainty |
|---|---|---|
| BMI, as an add-on | −1.38 kg/m² (95% CI −2.39 to −0.38) | Low |
| LDL cholesterol, triglycerides | No difference from control | Low |
| Glucose, insulin, hirsutism, menstrual regularity | Insufficient evidence to conclude | — |
| Quality of life, mental health, cost-effectiveness | No studies at all | — |
The bottom row means nobody has looked, which is different from “no benefit found”. For a condition where the psychological burden is a large part of what people want treated, and where cost decides who can have the drug at all, the literature is silent.
The analysis that reads more positively
A 2023 meta-analysis in BMC Endocrine Disorders pooled 11 randomized trials covering 840 women and reported something the 2026 review did not: an improvement in the natural pregnancy rate, at a risk ratio of 1.72 (95% CI 1.22 to 2.43).[2] It also reported improvements in menstrual cyclicity, insulin sensitivity, body measurements and hormonal indexes. A separate review of weight-lowering drugs and natural fertility found a single GLP-1 trial: 80 women, with semaglutide added to metformin raising the pregnancy rate from 15% to 35%. The wider trial record on PCOS and fertility is in our PCOS and fertility reading list.
So two pooled analyses of a similar-sized literature reach different levels of confidence about the reproductive outcomes. That is ordinary when the underlying trials are small and measure things differently. The reason to weight the more cautious one is its method, not its date: it registered its protocol in advance and graded the certainty of each finding, which is the machinery that stops a review from reading its own hopes into thin data.
One analysis reported a natural pregnancy rate 1.72 times that of controls; the registered 2026 review found the menstrual-regularity evidence insufficient to conclude anything.
Against metformin, which is what most people are already on
Metformin has been the default drug in PCOS for decades, so the practical question is rarely “GLP-1 or nothing”. A 2019 meta-analysis of 8 randomized trials compared them directly.[3] Whether taking the two together adds anything is a separate question, covered in metformin and a GLP-1 together.
- Insulin sensitivity improved more on a GLP-1 (standardized mean difference −0.40, 95% CI −0.74 to −0.06).
- BMI fell further on a GLP-1 (standardized mean difference −1.02, 95% CI −1.85 to −0.19), as did abdominal girth.
- Nausea and headache were more common on the GLP-1 than on metformin.
- Everything else measured showed no significant difference between them.
The authors’ own summary is that a GLP-1 might be a good choice for women with PCOS and obesity, particularly with insulin resistance, and that the available evidence is inconclusive.[3] Both halves are theirs.
The timing problem
PCOS is among the most common causes of infertility, so a large share of the women taking these drugs for it are doing so because they want to conceive. The Wegovy label puts a number on the gap it wants: two months, minimum, between the last dose and trying. Semaglutide clears slowly, and that is why the label sets the interval.[4]
There is a second-order version of the same issue. Weight loss can restore ovulation before anyone plans for it, and cycles that were unpredictable for years becoming regular is exactly the situation in which an unplanned pregnancy happens (other period changes on these drugs are in our period page). If that is not what you want yet, contraception is part of starting the drug, not a later conversation. If you take an oral contraceptive, our birth control piece covers which GLP-1 interferes with it and for how long.
Whoever prescribes, tell them if pregnancy is in your plans, because it changes the timing above. Some services place GLP-1 care inside a women’s or hormone practice. Hormonally Balanced, a physician-led women’s hormone practice in Massachusetts, prescribes semaglutide or tirzepatide after a full consultation in the seven states it serves. Gatlan runs weight loss as one path in a hormone and longevity clinic, with labs before treatment, and Joi + Blokes began with hormone programs for women and men before adding GLP-1s. Four sellers we track have a page for PCOS itself: Allara Health and PCOS Sisters build their care around it, and Gaya Wellness and Midi Health list it among the conditions they treat.
Twentyeight Health, a women’s health service best known for birth control, offers a Weight Care program in 22 states: a $19.99 Complete Care membership covers provider visits and messaging, and FDA-approved GLP-1s such as Wegovy are billed separately by the pharmacy, often through insurance or Medicaid.
Alloy and Steady State Health are built around midlife and menopause care rather than PCOS, so check the fit before you sign up. Eve and Nurx are women’s telehealth brands, and Eve sells compounded GLP-1s beside brand Ozempic, Wegovy and Mounjaro, but neither lists a PCOS program on its site. Tru2u, an Oregon women’s wellness brand, lists compounded semaglutide and tirzepatide as injections or oral tablets. To compare sellers on price and licensure, our semaglutide board for PCOS and the tirzepatide version rank every one we track, with the figures from these reviews set beside the list.
What nobody can tell you yet
- Whether it helps the symptoms you may care about most. Hirsutism and menstrual regularity both sit in the insufficient-evidence column of the newest review.[1]
- Whether it helps how you feel. No trial has measured quality of life or mental health in this population at all.[1]
- What happens long term. The trials are short; PCOS is not.
- Whether it is worth the money for you. No cost-effectiveness study exists,[1] and off-label use makes coverage harder. Our insurance section tracks what plans publish and the prior authorization letter generator assembles a submission.
Frequently Asked Questions
References
- 1.Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome — a systematic review and meta-analysis European Journal of Endocrinology. 2026. PMID: 41701618.
- 2.Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review BMC Endocrine Disorders. 2023. PMID: 37940910.
- 3.Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis Reproductive BioMedicine Online. 2019. PMID: 31229399.
- 4.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 8.3 Females and Males of Reproductive Potential (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Compare the sellers
Related research
Best Injection for Weight Loss? Every Approved Shot, Ranked on Trial Data
Zepbound took off the most weight of any injection FDA has approved for weight, and beat semaglutide head to head. Wegovy has the proven cardiovascular benefit. Label and trial data on weight, side effects and dropouts, plus what is not approved yet.
8 min read
AOD-9604: What the Evidence Shows
AOD-9604, a growth hormone fragment, failed its obesity trials: in 536 adults, weight loss beyond placebo was under 1 kg and the developer ended the program in 2007. FDA advisers voted 12 to 0 against compounding it.
9 min read
MOTS-c: What the Evidence Shows, and What FDA Found
MOTS-c slowed weight gain and improved insulin sensitivity in mice. No published trial has given it to people, and there is no established human dose. The 503A bulks list leaves it out; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against 503A compounding under strict conditions.
11 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk
A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.
6 min read
GLP-1 Drugs and Parkinson's Disease: What LIXIPARK and Exenatide-PD3 Showed
A 2024 phase 2 trial of lixisenatide found less motor decline over a year in early Parkinson's. The 2025 phase 3 Exenatide-PD3 trial found none over two years, and a pooled analysis of four trials found no benefit. Semaglutide and tirzepatide are untested.
7 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Direct Meds
From $249/mo
Get started →HealthRX
From $165/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →